- Home
- ACHL vs RAND Comparison
ACHL vs RAND Comparison
Compare ACHL & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- RAND
- Stock Information
- Founded
- ACHL 2016
- RAND 1969
- Country
- ACHL United Kingdom
- RAND United States
- Employees
- ACHL N/A
- RAND N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- RAND Finance: Consumer Services
- Sector
- ACHL Health Care
- RAND Finance
- Exchange
- ACHL Nasdaq
- RAND Nasdaq
- Market Cap
- ACHL 46.8M
- RAND 47.5M
- IPO Year
- ACHL 2021
- RAND N/A
- Fundamental
- Price
- ACHL $1.14
- RAND $21.68
- Analyst Decision
- ACHL Buy
- RAND
- Analyst Count
- ACHL 2
- RAND 0
- Target Price
- ACHL $4.00
- RAND N/A
- AVG Volume (30 Days)
- ACHL 266.7K
- RAND 10.4K
- Earning Date
- ACHL 11-14-2024
- RAND 03-04-2025
- Dividend Yield
- ACHL N/A
- RAND 23.20%
- EPS Growth
- ACHL N/A
- RAND 123.39
- EPS
- ACHL N/A
- RAND 4.98
- Revenue
- ACHL N/A
- RAND $8,351,941.00
- Revenue This Year
- ACHL N/A
- RAND N/A
- Revenue Next Year
- ACHL N/A
- RAND N/A
- P/E Ratio
- ACHL N/A
- RAND $4.35
- Revenue Growth
- ACHL N/A
- RAND 16.96
- 52 Week Low
- ACHL $0.63
- RAND $12.92
- 52 Week High
- ACHL $1.76
- RAND $24.10
- Technical
- Relative Strength Index (RSI)
- ACHL 55.79
- RAND 67.07
- Support Level
- ACHL $1.12
- RAND $19.17
- Resistance Level
- ACHL $1.18
- RAND $21.28
- Average True Range (ATR)
- ACHL 0.05
- RAND 0.88
- MACD
- ACHL -0.00
- RAND 0.23
- Stochastic Oscillator
- ACHL 33.33
- RAND 86.02
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.